AMGN vs BIIB Comparison: AI Score, Valuation, Performance and Upside
Compare Amgen and Biogen by biosimilar competition, pipeline depth, Alzheimer's drug momentum, obesity drug ambitions, dividend yield, and valuation.
Use this Amgen vs Biogen comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
BIIB holds the edge across 3 of 5 key metrics in this comparison. BIIB leads on both 1-year return (+54.67%) and forward P/E quality (12.45x vs 15.62x for AMGN), a relatively favorable combination of momentum and valuation. AMGN leads on both revenue growth (5.80%) and operating margin (33.80%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BIIB (+9.86%) than for AMGN (-2.64%).
| Metric | AMGN | BIIB |
|---|---|---|
| AI score | 47.8 | 28.9 |
| AI rank | #617 | #2383 |
| Latest close | $366.05 | $197.74 |
| 1M return | +6.19% | -0.99% |
| 6M return | +6.53% | +14.55% |
| 1Y return | +19.75% | +54.67% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMGN | BIIB |
|---|---|---|
| 1Y ago | $11.84K (+18.4%) started 2025-07-23 | $15.1K (+51.0%) started 2025-07-23 |
| 5Y ago | $19.44K (+94.4%) started 2021-07-26 | $5.96K (-40.4%) started 2021-07-26 |
| 10Y ago | $39.04K (+290.4%) started 2016-07-25 | $6.88K (-31.2%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | AMGN | BIIB |
|---|---|---|
| Market cap | $197.69B | $30.41B |
| Trailing P/E | 25.51 | 22.17 |
| Forward P/E | 15.62 | 12.45 |
| Price/Sales | 4.57 | 1.99 |
| EV/Revenue | 6.53 | 3.29 |
| Analyst target | $356.62 | $226.29 |
| Target upside | -2.64% | +9.86% |
| Metric | AMGN | BIIB |
|---|---|---|
| Revenue growth | 5.80% | 1.90% |
| Earnings growth | 4.40% | 31.10% |
| EPS growth | +4.40% | +31.10% |
| FCF margin | +19.98% | +19.43% |
| Operating margin | 33.80% | 22.90% |
| Profit margin | 20.96% | 13.80% |
| ROIC proxy | 101.32% | 7.70% |
| Return on equity | 101.32% | 7.70% |
| Dividend yield | 2.75% | N/A |
| Beta | 0.40 | 0.16 |
| Debt/equity | 623.75 | 35.18 |
| Current ratio | 1.26 | 3.06 |
| Quick ratio | 0.85 | 2.02 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AMGN | BIIB |
|---|---|---|---|
| 1Y | Growth | +18.38% | +50.97% |
| CAGR | +18.43% | +51.12% | |
| Sharpe ratio | 0.59 | 1.21 | |
| Max drawdown | 16.57% | 14.34% | |
| Max daily drop | 5.14% | 8.17% | |
| Max wkly drop | 8.70% | 12.37% | |
| 5Y | Growth | +69.73% | -40.43% |
| CAGR | +11.18% | -9.86% | |
| Sharpe ratio | 0.37 | -0.27 | |
| Max drawdown | 24.86% | 67.59% | |
| Max daily drop | 7.14% | 8.17% | |
| Max wkly drop | 12.81% | 13.62% | |
| 10Y | Growth | +187.48% | -31.18% |
| CAGR | +11.15% | -3.67% | |
| Sharpe ratio | 0.37 | -0.00 | |
| Max drawdown | 24.86% | 72.66% | |
| Max daily drop | 9.58% | 29.23% | |
| Max wkly drop | 15.79% | 34.30% |
| Category | AMGN | BIIB |
|---|---|---|
| Company | AMGN | BIIB |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.